Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218127 · ClinicalTrials.gov registry record · Phase 2
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
A Phase 2 study of Opioid-Related Disorders and Heroin Dependence, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
- 1
- Study location
NCT00218127: Completed Phase 2 study of Opioid-Related Disorders and Heroin Dependence, sponsored by National Institute on Drug Abuse (NIDA).
NCT00218127 is a Phase 2 study of Opioid-Related Disorders and Heroin Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 142 participants, below the 344-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00218127, a Phase 2 study of Opioid-Related Disorders and Heroin Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
Heroin dependence remains a major addiction problem in the United States. The purpose of this study is to determine the effectiveness of levoacetyl methadol (ORLAAM) in treating heroin dependent individuals.
Conditions Studied
Interventions
- DRUG Levoacetyl Methadol
Study Locations (1)
Texas
- Department of Psychatiry, Mental Services - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2001-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
What the finished NCT00218127 record still lists
NCT00218127 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 344-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Levoacetyl Methadol is the first listed.
NCT00218127 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00218127 about?
NCT00218127 is a clinical study titled "Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens". Heroin dependence remains a major addiction problem in the United States. The purpose of this study is to determine the effectiveness of levoacetyl methadol (ORLAAM) in treating heroin dependent individuals.
What is the current status of trial NCT00218127?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2001-11. Estimated completion is 2005-07.
What conditions does trial NCT00218127 study?
This clinical trial studies the following conditions: Opioid-Related Disorders, Heroin Dependence.
What interventions are being tested in trial NCT00218127?
The interventions under investigation include: Levoacetyl Methadol (DRUG).
Who is sponsoring clinical trial NCT00218127?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00218127 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00218127's enrollment target sits among peer trials
142 23rd of 47 higher than 25 of 47 other Opioid-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
RECRUITING · Phase 2
-
Alternate-Day Buprenorphine Administration. Phase VII - 8
COMPLETED · Phase 2
-
Alternate Day Buprenorphine Administration, Phase IX - 14
COMPLETED · Phase 2
-
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
COMPLETED · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia